Pharmaceutical teams increasingly rely on deeper, higher‑quality biological data to understand disease from every angle. With the power of next-generation sequencing (NGS), you can generate richer insights, increase control over your data, and make faster decisions all directly within your lab.
NGS for pharmaceutical research and development
Faster results, simpler analyses, and lower costs to support drug discovery solutions and development
Make drug discoveries faster and smarter with NGS
Unlock deeper biological context across every method
Modern discovery requires integrating multiple layers of biology. By linking disease drivers, regulators, and downstream consequences, NGS solutions empower pharmaceutical teams to combine DNA panels, RNA‑Seq, CRISPR screens, and proteomics to move from trial‑and‑error to biology‑informed, precision-based discovery pipelines.
Bring sequencing in‑house and accelerate your pipeline
In‑lab NGS gives you:
- More control over timelines, sample batching, and data security
- Faster turnaround, enabling rapid iteration and reduced reliance on CRO cycles
- Cost savings, with benchtop systems that reduce run costs by up to 40%
- Seamless analysis, with push‑button workflows requiring no bioinformatics expertise
Unlock NGS insights to accelerate drug discoveries
This eBook provides powerful tools to interrogate data across pharmaceutical research methods from oncology research to genetic disease research, and more.
Download eBook
Your email address is never shared with third parties.
Illumina in-lab sequencing reimagined for modern pharmaceutical research and development
Pharmaceutical teams increasingly rely on deeper, higher‑quality biological data to understand disease from every angle. With the power of next-generation sequencing (NGS), you can generate richer insights, increase control over your data, and make faster decisions all directly within your lab.
A breakthrough in analysis speed, accuracy, and security with DRAGEN v4.4
Learn more about the transformative potential of DRAGEN v4.4, where state-of-the-art, fully-integrated technology empowers you to explore new frontiers in omic research applications with precision, scale, speed, and insight like never before.
Sample-to-answer solutions for drug discovery pipelines
Pharmaceutical teams increasingly rely on deeper, higher‑quality biological data to understand disease from every angle. With the power of next-generation sequencing (NGS), you can generate richer insights, increase control over your data, and make faster decisions all directly within your lab.
RNA sequencing
RNA provides dynamic insight into disease biology across actively expressed biomarkers, tissue‑specific signatures, treatment‑response pathways, and post-transcriptional regulation of drug resistance and responses. Illumina offers streamlined, proven RNA sequencing workflows for:
RNA‑Seq
Characterize entire transcriptomes, detect novel features, and quantify expression with gold‑standard Illumina workflows.
Small RNA‑Seq
Profile microRNAs and other short RNA species that regulate drug response, therapy resistance, and disease mechanisms.
Rapid, intuitive benchtop sequencing solutions
Fast, simple, and sustainable
Purpose‑built for pharma discovery, the MiSeq i100 Series delivers fast, easy benchtop sequencing with validated end‑to‑end DNA panel workflows. In addition, the MiSeq i100 Series delivers fast run times for targeted DNA panels, pre‑designed workflows for oncology, genetic disease research, and more.
Flexible and cost-effective for a wide range of applications
The NextSeq 550 Sequencing System enables pharmaceutical research teams to combine NGS along with array scanning capabilities across a range of applications in a single system.
Explore NextSeq 550 Sequencing System applications and methods
Expanded capabilities using innovative and intuitive workflows
The NextSeq 1000 and NextSeq 2000 Sequencing Systems offer pharmaceutical teams expanded configurations to reduce cost and waste while offering robust performance on proven and intuitive platforms.
Explore NextSeq 1000 & 2000 Sequencing Systems applications and methods
Single-cell sequencing
CRISPR perturbation at scale
Illumina and Broad Clinical Labs combine CRISPR Perturb‑seq to deliver rapid, consistent generation of large‑scale functional genomics data. These capabilities support the Illumina Billion Cell Atlas to help researchers characterize gene function, validate targets, and model disease mechanisms with confidence.
Learn more about CRISPR and Purturb-Seq in this press release
Learn about perturbation-rich data sets from the Illumina Billion Cell Atlas project
Single‑cell RNA‑Seq with Illumina Single Cell 3’ RNA Prep
Illumina Single Cell Prep and the 3' RNA workflow enable high‑throughput profiling of thousands to millions of cells, producing standardized, reproducible RNA‑Seq data ideal for cell‑type discovery, pathway analysis, and early target identification.
Multiomics for a more complete biological understanding
Approach discovery from multiple angles simultaneously, by reducing blind spots and enhancing mechanistic insight to decipher complex biology. Illumina multiomics solutions to enable you to profile genomics, transcriptomics, epigenomics, and proteomics for richer insights into the causes and consequences of disease in a single sample.
Multiomics
Characterize entire transcriptomes, detect novel features, and quantify expression with gold‑standard Illumina workflows.
Clinical research assays
Bridge discovery and clinical research using Illumina oncology, rare disease, infectious disease, reproductive health, and multiomic assay solutions.
Speak to a specialist
Interested in learning more about how to collaborate with Illumina or want to know more about instrument insourcing solutions? Fill out the form and a specialist will be in touch with you soon!
Speak to a specialist
Your email address is never shared with third parties.